Logo image of IBS.LS

IBERSOL SGPS SA (IBS.LS) Stock Fundamental Analysis

ELI:IBS - Euronext Lisbon - PTIBS0AM0008 - Common Stock - Currency: EUR

8.44  -0.02 (-0.24%)

Fundamental Rating

4

Overall IBS gets a fundamental rating of 4 out of 10. We evaluated IBS against 53 industry peers in the Hotels, Restaurants & Leisure industry. The financial health of IBS is average, but there are quite some concerns on its profitability. IBS is not valued too expensively and it also shows a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year IBS was profitable.
In the past year IBS had a positive cash flow from operations.
IBS had positive earnings in 4 of the past 5 years.
IBS had a positive operating cash flow in each of the past 5 years.
IBS.LS Yearly Net Income VS EBIT VS OCF VS FCFIBS.LS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M -50M 100M 150M

1.2 Ratios

IBS's Return On Assets of 2.32% is on the low side compared to the rest of the industry. IBS is outperformed by 60.00% of its industry peers.
IBS has a Return On Equity (4.95%) which is in line with its industry peers.
IBS's Return On Invested Capital of 3.03% is on the low side compared to the rest of the industry. IBS is outperformed by 73.33% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for IBS is significantly below the industry average of 11.62%.
Industry RankSector Rank
ROA 2.32%
ROE 4.95%
ROIC 3.03%
ROA(3y)10.54%
ROA(5y)5.26%
ROE(3y)19.9%
ROE(5y)6.52%
ROIC(3y)4.73%
ROIC(5y)N/A
IBS.LS Yearly ROA, ROE, ROICIBS.LS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20 -20 40

1.3 Margins

The Profit Margin of IBS (3.72%) is worse than 64.44% of its industry peers.
In the last couple of years the Profit Margin of IBS has declined.
The Operating Margin of IBS (4.91%) is worse than 73.33% of its industry peers.
IBS's Operating Margin has declined in the last couple of years.
The Gross Margin of IBS (48.89%) is worse than 60.00% of its industry peers.
In the last couple of years the Gross Margin of IBS has remained more or less at the same level.
Industry RankSector Rank
OM 4.91%
PM (TTM) 3.72%
GM 48.89%
OM growth 3YN/A
OM growth 5Y-6.14%
PM growth 3YN/A
PM growth 5Y-7.85%
GM growth 3Y4.13%
GM growth 5Y-0.15%
IBS.LS Yearly Profit, Operating, Gross MarginsIBS.LS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20 40 60

More info and screens

4

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), IBS is destroying value.
The number of shares outstanding for IBS remains at a similar level compared to 1 year ago.
IBS has more shares outstanding than it did 5 years ago.
The debt/assets ratio for IBS is higher compared to a year ago.
IBS.LS Yearly Shares OutstandingIBS.LS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M
IBS.LS Yearly Total Debt VS Total AssetsIBS.LS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M

2.2 Solvency

IBS has an Altman-Z score of 1.93. This is not the best score and indicates that IBS is in the grey zone with still only limited risk for bankruptcy at the moment.
IBS's Altman-Z score of 1.93 is in line compared to the rest of the industry. IBS outperforms 55.56% of its industry peers.
IBS has a debt to FCF ratio of 6.77. This is a slightly negative value and a sign of low solvency as IBS would need 6.77 years to pay back of all of its debts.
IBS has a Debt to FCF ratio (6.77) which is in line with its industry peers.
IBS has a Debt/Equity ratio of 0.69. This is a neutral value indicating IBS is somewhat dependend on debt financing.
IBS has a Debt to Equity ratio of 0.69. This is comparable to the rest of the industry: IBS outperforms 60.00% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.69
Debt/FCF 6.77
Altman-Z 1.93
ROIC/WACC0.5
WACC6.06%
IBS.LS Yearly LT Debt VS Equity VS FCFIBS.LS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 100M 200M 300M 400M

2.3 Liquidity

IBS has a Current Ratio of 1.38. This is a normal value and indicates that IBS is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.38, IBS is in the better half of the industry, outperforming 75.56% of the companies in the same industry.
A Quick Ratio of 1.28 indicates that IBS should not have too much problems paying its short term obligations.
Looking at the Quick ratio, with a value of 1.28, IBS is in the better half of the industry, outperforming 71.11% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.38
Quick Ratio 1.28
IBS.LS Yearly Current Assets VS Current LiabilitesIBS.LS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M

More info and screens

4

3. Growth

3.1 Past

IBS shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -88.97%.
The earnings per share for IBS have been decreasing by -13.58% on average. This is quite bad
IBS shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 10.51%.
IBS shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -1.46% yearly.
EPS 1Y (TTM)-88.97%
EPS 3YN/A
EPS 5Y-13.58%
EPS Q2Q%12.5%
Revenue 1Y (TTM)10.51%
Revenue growth 3Y13.12%
Revenue growth 5Y-1.46%
Sales Q2Q%16.68%

3.2 Future

IBS is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 17.95% yearly.
IBS is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 6.37% yearly.
EPS Next Y4.84%
EPS Next 2Y17.32%
EPS Next 3Y21.06%
EPS Next 5Y17.95%
Revenue Next Year8.97%
Revenue Next 2Y8.19%
Revenue Next 3Y6.6%
Revenue Next 5Y6.37%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
IBS.LS Yearly Revenue VS EstimatesIBS.LS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 100M 200M 300M 400M 500M
IBS.LS Yearly EPS VS EstimatesIBS.LS Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 0.5 -0.5 -1

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 21.10 indicates a rather expensive valuation of IBS.
Based on the Price/Earnings ratio, IBS is valued a bit cheaper than 68.89% of the companies in the same industry.
IBS is valuated rather cheaply when we compare the Price/Earnings ratio to 28.47, which is the current average of the S&P500 Index.
The Price/Forward Earnings ratio is 19.59, which indicates a rather expensive current valuation of IBS.
Based on the Price/Forward Earnings ratio, IBS is valued a bit cheaper than 62.22% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 92.74, IBS is valued rather cheaply.
Industry RankSector Rank
PE 21.1
Fwd PE 19.59
IBS.LS Price Earnings VS Forward Price EarningsIBS.LS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80

4.2 Price Multiples

Compared to the rest of the industry, the Price/Free Cash Flow ratio of IBS indicates a somewhat cheap valuation: IBS is cheaper than 75.56% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 8.2
EV/EBITDA N/A
IBS.LS Per share dataIBS.LS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6 8 10

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates IBS does not grow enough to justify the current Price/Earnings ratio.
A more expensive valuation may be justified as IBS's earnings are expected to grow with 21.06% in the coming years.
PEG (NY)4.36
PEG (5Y)N/A
EPS Next 2Y17.32%
EPS Next 3Y21.06%

More info and screens

6

5. Dividend

5.1 Amount

With a Yearly Dividend Yield of 5.98%, IBS is a good candidate for dividend investing.
Compared to an average industry Dividend Yield of 2.78, IBS pays a better dividend. On top of this IBS pays more dividend than 97.78% of the companies listed in the same industry.
Compared to an average S&P500 Dividend Yield of 2.28, IBS pays a better dividend.
Industry RankSector Rank
Dividend Yield 5.98%

5.2 History

The dividend of IBS is nicely growing with an annual growth rate of 31.58%!
Dividend Growth(5Y)31.58%
Div Incr Years1
Div Non Decr Years1
IBS.LS Yearly Dividends per shareIBS.LS Yearly Dividends per shareYearly Dividends per share 2019 2022 2023 2024 0.2 0.4 0.6

5.3 Sustainability

IBS pays out 122.87% of its income as dividend. This is not a sustainable payout ratio.
IBS's earnings are growing slower than its dividend. This means the dividend growth is not sustainable.
DP122.87%
EPS Next 2Y17.32%
EPS Next 3Y21.06%
IBS.LS Yearly Income VS Free CF VS DividendIBS.LS Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M -50M 100M 150M
IBS.LS Dividend Payout.IBS.LS Dividend Payout, showing the Payout Ratio.IBS.LS Dividend Payout.PayoutRetained Earnings

More info and screens

IBERSOL SGPS SA

ELI:IBS (2/4/2025, 7:00:00 PM)

8.44

-0.02 (-0.24%)

Chartmill FA Rating
GICS SectorConsumer Discretionary
GICS IndustryGroupConsumer Services
GICS IndustryHotels, Restaurants & Leisure
Earnings (Last)11-29 2024-11-29/amc
Earnings (Next)N/A N/A
Inst Owners22.43%
Inst Owner ChangeN/A
Ins Owners0.03%
Ins Owner ChangeN/A
Market Cap350.34M
Analysts83.33
Price Target11.83 (40.17%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 5.98%
Yearly Dividend0.7
Dividend Growth(5Y)31.58%
DP122.87%
Div Incr Years1
Div Non Decr Years1
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-20.44%
Min EPS beat(2)-25.74%
Max EPS beat(2)-15.13%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)5.23%
Min Revenue beat(2)0.18%
Max Revenue beat(2)10.27%
Revenue beat(4)4
Avg Revenue beat(4)6.97%
Min Revenue beat(4)0.18%
Max Revenue beat(4)10.27%
Revenue beat(8)6
Avg Revenue beat(8)5.69%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-2.11%
PT rev (3m)-1.83%
EPS NQ rev (1m)0%
EPS NQ rev (3m)16.67%
EPS NY rev (1m)-12.63%
EPS NY rev (3m)-9.22%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)8.74%
Revenue NY rev (1m)2.16%
Revenue NY rev (3m)2.16%
Valuation
Industry RankSector Rank
PE 21.1
Fwd PE 19.59
P/S 0.77
P/FCF 8.2
P/OCF 4.55
P/B 1.03
P/tB 1.43
EV/EBITDA N/A
EPS(TTM)0.4
EY4.74%
EPS(NY)0.43
Fwd EY5.11%
FCF(TTM)1.03
FCFY12.19%
OCF(TTM)1.86
OCFY21.99%
SpS10.95
BVpS8.22
TBVpS5.89
PEG (NY)4.36
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 2.32%
ROE 4.95%
ROCE 3.84%
ROIC 3.03%
ROICexc 4.07%
ROICexgc 5.24%
OM 4.91%
PM (TTM) 3.72%
GM 48.89%
FCFM 9.4%
ROA(3y)10.54%
ROA(5y)5.26%
ROE(3y)19.9%
ROE(5y)6.52%
ROIC(3y)4.73%
ROIC(5y)N/A
ROICexc(3y)6.92%
ROICexc(5y)N/A
ROICexgc(3y)9.56%
ROICexgc(5y)N/A
ROCE(3y)5.99%
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5Y-20.96%
ROICexc growth 3YN/A
ROICexc growth 5Y-13.96%
OM growth 3YN/A
OM growth 5Y-6.14%
PM growth 3YN/A
PM growth 5Y-7.85%
GM growth 3Y4.13%
GM growth 5Y-0.15%
F-Score6
Asset Turnover0.62
Health
Industry RankSector Rank
Debt/Equity 0.69
Debt/FCF 6.77
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales 7.55%
Interest Coverage 250
Cash Conversion N/A
Profit Quality 252.84%
Current Ratio 1.38
Quick Ratio 1.28
Altman-Z 1.93
F-Score6
WACC6.06%
ROIC/WACC0.5
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)12.95%
Cap/Sales(5y)11.86%
Profit Quality(3y)143.97%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-88.97%
EPS 3YN/A
EPS 5Y-13.58%
EPS Q2Q%12.5%
EPS Next Y4.84%
EPS Next 2Y17.32%
EPS Next 3Y21.06%
EPS Next 5Y17.95%
Revenue 1Y (TTM)10.51%
Revenue growth 3Y13.12%
Revenue growth 5Y-1.46%
Sales Q2Q%16.68%
Revenue Next Year8.97%
Revenue Next 2Y8.19%
Revenue Next 3Y6.6%
Revenue Next 5Y6.37%
EBIT growth 1Y-21.52%
EBIT growth 3YN/A
EBIT growth 5Y-7.51%
EBIT Next Year301.66%
EBIT Next 3Y75.66%
EBIT Next 5Y56.64%
FCF growth 1Y-28.97%
FCF growth 3YN/A
FCF growth 5Y20.7%
OCF growth 1Y-29.99%
OCF growth 3Y45.49%
OCF growth 5Y10.5%